Apr 29, 2020
AIM ImmunoTech's CEO to Present at Maxim's Infectious Disease Virtual Conference

Apr 20, 2020
AIM ImmunoTech's CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020

Apr 06, 2020
AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic

Apr 06, 2020
AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers

Mar 31, 2020
AIM ImmunoTech Reports 2019 Year-end Financial Results

Mar 26, 2020
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

Mar 09, 2020
AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19

Feb 27, 2020
AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic

Feb 18, 2020
AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

Feb 12, 2020
AIM ImmunoTech's CEO to Appear Live Today on FOX Business Network's The Claman Countdown and Cheddar's Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus

 4   5   6   7   8     9    10   11   12   13   14